» Articles » PMID: 22553500

Disruption of Protein Quality Control in Parkinson's Disease

Overview
Specialty General Medicine
Date 2012 May 4
PMID 22553500
Citations 74
Authors
Affiliations
Soon will be listed here.
Abstract

Parkinson's disease (PD), like a number of neurodegenerative diseases associated with aging, is characterized by the abnormal accumulation of protein in a specific subset of neurons. Although researchers have recently elucidated the genetic causes of PD, much remains unknown about what causes increased protein deposition in the disease. Given that increased protein aggregation may result not only from an increase in production, but also from decreased protein clearance, it is imperative to investigate both possibilities as potential PD culprits. This article provides a review of the systems that regulate protein clearance, including the ubiquitin proteasome system (UPS) and the autophagy-lysosomal pathway. Literature implicating failure of these mechanisms-such as UPS dysfunction resulting from environmental toxins and mutations in α-synuclein and parkin, as well as macroautophagic pathway failure because of oxidative stress and aging-in the pathogenesis of PD is also discussed.

Citing Articles

Evolving Landscape of Parkinson's Disease Research: Challenges and Perspectives.

Tenchov R, Sasso J, Zhou Q ACS Omega. 2025; 10(2):1864-1892.

PMID: 39866628 PMC: 11755173. DOI: 10.1021/acsomega.4c09114.


Therapeutic Effect of Extract on a Cell System Model for Parkinson's Disease.

Ho D, Kim H, Nam D, Seo M, Park S, Kim D NeuroSci. 2024; 5(3):301-314.

PMID: 39483283 PMC: 11469749. DOI: 10.3390/neurosci5030024.


Exploring the Potential of Antidiabetic Agents as Therapeutic Approaches for Alzheimer's and Parkinson's Diseases: A Comprehensive Review.

Koshatwar M, Acharya S, Prasad R, Lohakare T, Wanjari M, Taksande A Cureus. 2023; 15(9):e44763.

PMID: 37809189 PMC: 10556988. DOI: 10.7759/cureus.44763.


Role of NFE2L1 in the Regulation of Proteostasis: Implications for Aging and Neurodegenerative Diseases.

Chandran A, Oliver H, Rochet J Biology (Basel). 2023; 12(9).

PMID: 37759569 PMC: 10525699. DOI: 10.3390/biology12091169.


Attenuation of Dopaminergic Neurodegeneration in a Parkinson's Model through Regulation of Xanthine Dehydrogenase (XDH-1) Expression by the RNA Editase, ADR-2.

Starr L, McKay L, Peter K, Seyfarth L, Berkowitz L, Caldwell K J Dev Biol. 2023; 11(2).

PMID: 37218814 PMC: 10204437. DOI: 10.3390/jdb11020020.


References
1.
SantaCruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M . Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005; 309(5733):476-81. PMC: 1574647. DOI: 10.1126/science.1113694. View

2.
Cuervo A, Stefanis L, Fredenburg R, Lansbury P, Sulzer D . Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004; 305(5688):1292-5. DOI: 10.1126/science.1101738. View

3.
Iwata A, Riley B, Johnston J, Kopito R . HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J Biol Chem. 2005; 280(48):40282-92. DOI: 10.1074/jbc.M508786200. View

4.
Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg M . alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002; 4(2):160-4. DOI: 10.1038/ncb748. View

5.
Bisaglia M, Mammi S, Bubacco L . Kinetic and structural analysis of the early oxidation products of dopamine: analysis of the interactions with alpha-synuclein. J Biol Chem. 2007; 282(21):15597-605. DOI: 10.1074/jbc.M610893200. View